Proteomic-based identification of multiple pathways underlying n-butylidenephthalide-induced apoptosis in LNCaP human

Cheng-Yoong Pang1, Sheng-Chun Chiu, Horng-Jyh Harn

  • 1Department of Medical Research, Buddhist Tzu Chi General Hospital, Hualien 970, Taiwan.

Insights

Butylidenephthalide (BP) inhibits human prostate cancer cell growth by inducing cell cycle arrest and apoptosis. Proteomic analysis revealed BP affects key proteins involved in cell cycle regulation, apoptosis, and endoplasmic reticulum stress.

Area of Science:

  • Oncology
  • Molecular Biology
  • Proteomics

Background:

  • Butylidenephthalide (BP) exhibits known cancer-preventive properties.
  • Limited research exists on BP's effects on human prostate cancer cells.

Purpose of the Study:

  • To elucidate the anticancer mechanism of BP in LNCaP human prostate cancer cells using proteomic approaches.

Main Methods:

  • Proteomic-based approaches were employed.
  • LNCaP human prostate cancer cells were treated with BP.
  • Cell viability, cell cycle phase distribution, and protein expression levels were analyzed.

Main Results:

  • BP decreased LNCaP cell viability in a dose- and time-dependent manner.
  • BP induced G0/G1 phase cell cycle arrest, altering levels of cell cycle regulatory proteins (CCND1, CDK2, PCNA, CDKN2A, CDKN1A, SFN).
  • Proteomic analysis identified 48 differentially expressed proteins, highlighting roles in apoptosis and endoplasmic reticulum stress, including FAS, AIFM1, BIK, CYCS, SFN, PPP2R1A, CALR, HSPA5, DDIT3, and ERN1.

Conclusions:

  • BP exhibits anticancer effects against human prostate cancer cells.
  • BP-induced apoptosis involves multiple pathways, including the FAS-dependent pathway, mitochondrial pathway, and endoplasmic reticulum stress pathway.